Get the Stockscreener App
4.56
2.70%
+0.12
After Hours:
4.56
OmniAb Inc stock is currently priced at $4.56, with a 24-hour trading volume of 467.90K.
It has seen a +2.70% increased in the last 24 hours and a -14.93% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.47 pivot point. If it approaches the $4.57 resistance level, significant changes may occur.
Previous Close:
$4.44
Open:
$4.45
24h Volume:
467.90K
Market Cap:
$536.28M
Revenue:
$34.16M
Net Income/Loss:
$-50.62M
P/E Ratio:
-28.59
EPS:
-0.1595
Net Cash Flow:
$703.00K
1W Performance:
+0.00%
1M Performance:
-14.93%
6M Performance:
+1.11%
1Y Performance:
+32.17%
1D Range:
$4.4074
$4.63
52W Range:
$3.14
$6.715
OmniAb Inc Stock (OABI) Company Profile
Name
OmniAb Inc
Sector
Industry
Phone
510 250 7800
Address
5980 Horton Street, Suite 600, EmeryVille
OmniAb Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
OmniAb Inc Stock (OABI) Latest News
USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates
Zacks Investment Research
Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buying
Benzinga
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
Zacks Investment Research
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
OmniAb Inc Stock (OABI) Financials Data
OmniAb Inc (OABI) Revenue 2024
OABI reported a revenue (TTM) of $34.16 million for the quarter ending December 31, 2023, a -42.17% decline year-over-year.
OmniAb Inc (OABI) Net Income 2024
OABI net income (TTM) was -$50.62 million for the quarter ending December 31, 2023, a -126.65% decrease year-over-year.
OmniAb Inc (OABI) Cash Flow 2024
OABI recorded a free cash flow (TTM) of $703.00 thousand for the quarter ending December 31, 2023, a +103.39% increase year-over-year.
OmniAb Inc (OABI) Earnings per Share 2024
OABI earnings per share (TTM) was -$0.508 for the quarter ending December 31, 2023, a -176.24% decline year-over-year.
About OmniAb Inc
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
3.18%
Cap:
|
Volume (24h):